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Abstract 20	
Conjugate vaccines against Streptococcus pneumoniae have significantly reduced 21	
diseases caused by serotypes included in those vaccines; however, there is still need for 22	
vaccines that confer serotype-independent protection. In the current study, we have 23	
constructed a library of conserved surface proteins from S. pneumoniae and screened 24	
for IL-17A and IL-22 production in human immune cells obtained from adenoidal/tonsillar 25	
tissue of children and IL-17A production from splenocytes from mice that were 26	
immunized with a killed whole cell vaccine or previously exposed to pneumococcus. A 27	
positive correlation was found between rankings of proteins from human IL-17A and IL-28	
22 screens, but not between human and mouse screens. All proteins were tested for 29	
protection against colonization, from which we identified protective antigens that are IL-30	
17A dependent. We found that the likelihood of finding a protective antigen is 31	
significantly higher from groups of proteins ranked in the top 50% of all three screens 32	
than for groups of proteins ranked in the bottom 50% of all three. The results thus 33	
confirmed the value of such screens to identify Th17 antigens. Further, these 34	
experiments have evaluated and compared the breadth of human and mouse Th17 35	
responses to pneumococcal colonization and enabled the identification of potential 36	
vaccine candidates based on immunological responses in mouse and human cells.   37	
 38	
  39	
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Introduction  40	
Streptococcus pneumoniae, or pneumococcus, is a Gram-positive bacterium that 41	
is a major cause of morbidity and mortality in infants, toddlers and the elderly in both 42	
developed and developing countries. Introduction of the first conjugate vaccine PCV7, 43	
followed by PCV10 and PCV13, has greatly reduced the incidence of invasive disease 44	
and colonization caused by the serotypes included in these vaccines (1). Despite the 45	
success of these vaccines, serotypes that are not included in these vaccines pose an 46	
emerging threat. Indeed, there are at least 97 identified pneumococcal serotypes with 47	
variability in regional distribution of predominant serotypes; furthermore, the 48	
phenomenon of serotype replacement has reduced the impact of these vaccines in 49	
many settings (2).  50	
While it is well established that anticapsular antibodies are sufficient to prevent 51	
invasive disease such as pneumonia, meningitis and sepsis, other mechanisms of 52	
immunity may also play important roles. Either live exposure to pneumococcus or 53	
immunization with killed whole cell vaccine (SPWCV) can induce CD4+ Th17 dependent 54	
protection against nasopharyngeal colonization in mice (3-5). The reduction in 55	
colonization in mice is dependent on generating pneumococcus-specific Th17 immunity 56	
and recruiting neutrophils to the mucosal site (3).  57	
Evidence is accumulating to suggest that Th17-based immunity is alsounity 58	
important for protection against pneumococcus in humans. The existence of 59	
pneumococcal-specific Th17-type T cells was demonstrated in both children and adults 60	
by analysing Th17 responses to a killed preparation of pneumococcus (pneumococcal 61	
whole cell antigen, WCA) or individual pneumococcal antigens (6). Furthermore, the 62	
frequency of pneumococcal-specific Th1 and Th17 CD4+ T cells within mucosal 63	
lymphoid tissue demonstrates age-dependent increases, likely due to cumulative 64	
exposure to pneumococcus (7). In an experimental human challenge model, lung IL-65	
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17A-secreting CD4+ memory T-cells were detected following intentional pneumococcal 66	
carriage (8).  Furthermore, patients with autosomal dominant hyper-IgE syndrome (Job’s 67	
syndrome), who lack the ability to generate memory Th17 cells due to mutations in the 68	
stat3 gene, are highly susceptible to recurrent pneumococcal infections (9, 10).  More 69	
recently two studies provided support for a role of IL-17A in pneumococcal carriage in 70	
children:  a specific polymorphism of the IL-17 gene (G-152A) in Finnish children (11) 71	
and decreased IL-17A secretion in Fijian children (12) were associated with increased 72	
risk of pneumococcal carriage. 73	
In addition to Th17 cells, antibodies are also likely to play an important role in 74	
protection against pneumococcal disease. A SPWCV consisting of WCA and aluminium 75	
adjuvant given subcutaneously or intramuscularly elicits anti-protein antibody-mediated 76	
protection against pneumococcal pneumonia and sepsis in mice, which can also be 77	
reproduced by passive transfer of antibodies obtained from rabbits immunized with 78	
SPWCV (13). Naturally acquired protection against pneumococcal disease in humans 79	
was recently shown to depend largely on antibody to protein antigens rather than to 80	
capsular polysaccharides (14). 81	
As a consequence, there has been a concerted effort over many years to identify 82	
protective protein antigens against pneumococcal disease (15, 16). Traditional methods, 83	
such as protein separation by two-dimensional gel electrophoresis and identification by 84	
mass spectroscopy, have been used to identify proteins from the cell wall fraction of 85	
pneumococcus that interact with convalescent sera from patients (17). As another 86	
approach, libraries of purified surface proteins have been used to identify antigens that 87	
may induce protection against pneumococcal invasive disease (18). A display library 88	
expressing 15-150 amino acid fragments of the pneumococcal proteome was used to 89	
identify proteins that interact with serum from infected individuals, leading to selection of 90	
StkP and PcsB as candidate antigens (19).   91	
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Using similar approaches, other investigators have used pneumococcal antigens 92	
to identify potentially protective T-cell antigens. Putative Th17-eliciting antigens were 93	
identified from the soluble fraction of the WCA using preparative SDS gel 94	
electrophoresis followed by mass spectroscopy (20). In a more comprehensive approach 95	
using the ATLAS© system, an expression library containing >96% of predicted 96	
pneumococcal proteins was used to identify antigens recognized by Th17 cells from 97	
SPWCV-immunized mice (21) and from human volunteers naturally exposed to 98	
pneumococcus (22).  99	
The studies cited above used either mouse splenocytes or human peripheral 100	
blood mononuclear cells (PBMCs) as a source of immune cells. There have been some 101	
studies using arguably a more relevant source of immune cells, the human mucosal 102	
lymphoid tissue, probed for Th17 responses following stimulation with a small number of 103	
pneumococcal proteins (23-25), but a more comprehensive analysis of the range of 104	
Th17 responses to the pneumococcal proteome has not been performed. Here, we 105	
constructed a protein library consisting of genetically conserved pneumococcal surface 106	
proteins.  We used this library to screen human adenoidal cells for Th17-cytokine-107	
inducing antigens and compared these human responses to those observed from 108	
splenocytes from mice immunized with SPWCV or exposed to pneumococcus. Positive 109	
correlations between two human screens but no correlations between human and 110	
murine screens were observed. Several antigens were identified that subsequently 111	
showed IL-17A-dependent protection against pneumococcal colonization in mice.  112	
 113	
Results  114	
 115	
Age-dependent immune response to WCA 116	
We obtained 35 adenoidal samples from children undergoing adenoidectomy and 117	
analyzed IL-17A and IL-22 production in response to stimulation with WCA in 33 of these 118	
	 6	
samples. As shown in Figure 1, there was an age-dependent, significant increase in IL-119	
17A responses (p=0.0235, r=0.3996) and IL-22 (p=0.0429, r=0.3786). The finding that 120	
immune responses to pneumococcus in adenoids in children tend to increase with age 121	
supports the hypothesis that these adenoidal cells may represent a good source of 122	
responsive immune cells for antigen discovery.  123	
Screening antigens using human adenoidal cells 124	
Fifty-six recombinant proteins out of 81 genetic constructs were successfully expressed 125	
in E. coli and purified using Ni-NTA chromatography. These proteins were further 126	
purified by gel filtration before being used in stimulation experiments with adenoidal cells. 127	
Due to the limited number of cells obtained from each adenoid, we were able to screen 128	
all 56 proteins in 13 samples and only a subgroup of these proteins with the other 22 129	
human samples. Both we and others have showed that IL-17A production in human in 130	
response to pneumococcal whole cell or purified pneumococcal proteins are mostly due 131	
to stimulation of memory T cells (26, 27). The results of IL-17A and IL-22 production in 132	
these 13 samples after subtracting the baseline responses following incubation with 133	
medium alone are shown in Figure 2. IL-17A responses from each protein were 134	
generally in the range of 50-100 pg/ml (mean 157 pg/ml), with WCA having the highest 135	
responses (far right) (Figure 2A). IL-22 responses were generally higher than IL-17A, 136	
mostly ranging from 200-600 pg/ml (Figure 2B).  137	
Screening antigens using murine immune cells 138	
While colonization and infection models in mice are widely used to test candidate 139	
pneumococcal vaccines, the extent to which murine immune responses mimic human 140	
responses is still unclear. A comparison of the responses of murine and human immune 141	
cells following stimulation with proteins from the same pneumococcal library may 142	
improve our understanding of the differences between and common features of these 143	
two species.  To this end, murine splenocytes were obtained from mice either 144	
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immunized with SPWCV or previously colonized with a serotype 6B pneumococcal strain 145	
for 4 weeks (the latter model may more closely mimic pneumococcal exposure in 146	
humans).  Both methods result in the generation of protective and antigen-specific 147	
memory CD4+ T cell responses against nasopharyngeal colonization in mice (3, 13, 28, 148	
29), and we have confirmed that these mice were protected from nasal colonization 149	
(data not shown). IL-17A responses following stimulation of splenocytes from these two 150	
mice models with the library of proteins are shown in Figure 3. Stimulation with SPWCA 151	
and proteins in splenocytes from naïve mice did not generate any IL-17A (data not 152	
shown). Responses in SPWCV immunized mice, most of which were between 50 and 153	
200 pg/ml (Figure 3A) were generally lower than those in pneumococcus-exposed mice, 154	
most of which were between 100 and 500 pg/ml (Figure 3B). SPWCA induced the 155	
largest responses in both mouse models (far right data points). 156	
Evaluation of antigens in colonization models. Next, we tested the ability of the 157	
library of proteins to provide protection against colonization in mice when used as 158	
immunogens. Mice were immunized intranasally twice at a one-week interval with one of 159	
the top 5 murine proteins (10 µg/dose) and 1µg of CT; control mice received 1 µg of CT 160	
alone. The whole library was tested in six different experiments, as shown in Figure 4. A 161	
total of 18 constructs (16 antigens) was found to be protective in this model; their 162	
identities and predicted functions are listed in table 1.  163	
Protection against colonization is IL-17A dependent 164	
We have shown previously that protection against colonization is dependent on CD4+ 165	
Th17 cells whereas antibodies directed against antigens contained in the whole cell 166	
vaccine were not protective in the colonization model (3, 13, 28). We then tested 167	
whether the protection afforded by these antigens is dependent on IL-17A production. To 168	
facilitate the experiment, we chose combinations of the three antigens which induced 169	
greatest responses either in murine screens (SP0648-3, SP0757 and SP1500) or in the 170	
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human IL-17A screen (SP0648-1, SP0662-1 and SP0742) and tested the dependence of 171	
protection on IL-17A. Mice were immunized intranasally and were given either anti-IL17A 172	
antibody or an isotype control antibody both one day before and 3 days after challenge 173	
inoculation with S. pneumoniae. As shown in Figure 5, immunization with both antigen 174	
combinations (Figure 5A & B) protected mice from colonization while protection was 175	
abolished in immunized mice treated with antibody directed against IL-17A, thus 176	
confirming the role of this cytokine in this model.  177	
Ranking of antigens and correlation between screens 178	
Proteins were ranked in each screen as explained in the methods section. We compared 179	
the ranking results of SPWCV-immunized mice, pneumococcal exposed mice and 180	
human samples with respect to IL-17A and IL-22. There was a weak correlation between 181	
the results from immune cells in the two different mouse models (Figure S1A) while 182	
there was a strong positive correlation between the IL-17A and IL-22 screens using 183	
human cells (Figure 6). No statistically significant correlation was found between the IL-184	
17A screen results using human cells and cells from SPWCV-immunized mice (Figure 185	
S1B) or mice previously exposed to pneumococcus (Figure S1C), nor was any 186	
correlation between human cell IL-22 production and either mouse screen found (data 187	
not shown). 188	
Validation of the screening method 189	
We analyzed how well each screen predicted protection against colonization. Overall, 190	
the rate of protection among the proteins in the library is quite high (18/56, 32.1%; Figure 191	
4) comparing to regular screening with whole genome (21), which probably reflects the 192	
way the library was designed. Antigens were categorized as belonging either to the top 193	
or bottom 50%, based on their rankings in each screen. We then compared the “hit rate” 194	
(i.e. identifying an antigen that is protective in the colonization model) in the top 50% 195	
responders versus the bottom 50% responders in the two murine and one human IL-17A 196	
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screens. While the hit rates were higher in the top 50% responders, none of these 197	
differences was significant (table 2). In contrast, when we identified antigens that were 198	
highly ranked either in two screens or amongst all three screens, the hit rates were 199	
significantly higher:  for example, for antigens that were in the top 50% rank in all three 200	
screens, the hit rate was 61.5%, significantly higher than the 11.1% hit rate for antigens 201	
that fall into the bottom 50% in all three screens (p=0.0306 by Fisher’s exact test), and 202	
about twice the hit rate for the whole library, which trended towards significance (p=0.06, 203	
by Fisher’s). When the same analysis was done with two murine and human IL-22 204	
screen, a similar result was obtained. The hit rate in the top 50% rank in all three 205	
screens was 58.5%, comparing to 8.3% in the bottom of all three screens (p=0.009).  206	
Discussion 207	
Using a conserved pneumococcal surface protein library, we stimulated human 208	
and murine immune cells in order to identify antigens that elicit IL-17A and IL-22 209	
responses and tested which of them confer protection against pneumococcal 210	
colonization following intranasal immunization in mice.  Overall, we found that antigens 211	
that more consistently induced cytokine responses across both murine and human cell 212	
screens were more likely to be protective . In addition, we identified many antigens that 213	
showed IL-17A-dependent protection against pneumococcal colonization in mice.   214	
One goal of this study was to investigate whether the immune responses to 215	
pneumococcus in murine and human cells are correlated and whether murine screens 216	
could predict the results of the human screen. IL-17A and IL-22 responses of human 217	
cells were highly correlated to each other, which confirms our previous findings that IL-218	
17A and IL-22 responses to WCA in children’s PBMC are highly correlated (6). However, 219	
there was no correlation between the rankings of the IL-17A responses to our protein 220	
library in murine and human screens, suggesting that there are differences in responses 221	
that are both host- (mouse vs. human) and exposure-dependent (live vs. killed bacteria).  222	
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The lack of correlation between exposed mouse and human cells could be 223	
explained by many factors. First, there are clear differences between mouse and human 224	
immune systems (30). Furthermore, the local environment for pneumococcal 225	
colonization might not be the same in mice and human, given growing evidence of the 226	
influence of microbiota on immune development (31). Thirdly, most children may have 227	
been exposed to pneumococcus many times, after which they may have generated high 228	
Th17 response to nonprotective proteins whereas the mice were only exposed to 229	
pneumococcus or pneumococcal antigens for a short defined period in our experiment. 230	
Lastly, in addition to intrinsic differences between mouse and human immune cells, we 231	
are comparing human adenoidal mucosal cells to murine splenocytes, cells from very 232	
different compartments.  233	
Despite these differences, we were able to identify several protective candidates 234	
by combining the three screens, which suggests that screening for cytokine production 235	
using cells from different sources may be a useful method to identify cytokine-mediated 236	
protection. Indeed, we found that the protective hit rate was highest in the pool of 237	
proteins that induced higher responses in all the screens. The 16 protective antigens 238	
that we identified have not previously been reported as conferring protection, with the 239	
single exception of SP1683 which was recently reported as a Th17-dependent antigen 240	
which protects against colonization while this manuscript was being preparared (32).   241	
While protection against colonization by any single antigen did not approach that of 242	
SPWCV in mouse models (Figure 4), a combination of three antigens significantly 243	
improved the protective efficacy of any individual protein antigen (Figure 5). This 244	
suggests that a candidate protein-based vaccine should likely comprise several antigens, 245	
to maximize protection and coverage.  246	
Another important implication of our work is that immune responses 247	
demonstrable in mouse models do not accurately predict those of humans.  In light of 248	
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the recent failure of at least two different protein vaccine formulations(33, 34) to provide 249	
protection against colonization, one is left wondering whether excessive reliance on 250	
mouse models may be responsible.  Clearly,murine models are much more convenient 251	
and practical for large scale screening and identification of potential candidates, as were 252	
performed here.  However, prior to performing expensive and time-consuming proof-of-253	
concept studies of impact on colonization in toddler or infant subjects, perhaps other 254	
approaches that can serve to de-risk the process may be useful.  One approach would 255	
be to try to establish correlates of protection, by performing longitudinal studies of 256	
colonization and systemic T cell responses in children.  Another approach may be to test 257	
promising candidates in intentional challenge studies in humans (8, 35).  A potential 258	
caveat to this strategy is that intentional challenge studies are performed in adults, 259	
whereas the intended target population of these vaccines is generally toddlers and 260	
infants.  However, such studies could still be helpful in providing a gating strategy: 261	
impact on carriage density or duration of carriage in a properly powered study of 262	
intentionally challenged adult volunteers could be used to decide whether or not to 263	
pursue studies of the candidate vaccine in younger subjects. 264	
A potential limitation of our study is that children undergoing adenoidectomy, who 265	
are the only practical and ethically acceptable source of pediatric NALT, may be 266	
immunologically distinct from a randomly selected sample of healthy children. 267	
Nevertheless, previous studies have confirmed a very similar pattern of acquisition of 268	
serum antibodies with age in both these children and healthy controls.  Furthermore, 269	
rates of pneumococcal colonization at the time of surgery are also similar to those seen 270	
in healthy children of comparable age (36). Another potential limitation is that some 271	
children may have had limited prior pneumococcal exposure at the time of surgery. 272	
However previous studies have shown that the majority of such children have mucosal 273	
specific immune responses to pneumococcal protein antigens (37). 274	
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 In summary, we report here the results of screening of human and mouse cells 275	
following exposure to pneumococcus using a library of conserved pneumococcal 276	
proteins. We believe the use of human and murine cells for this type of screening can 277	
inform the selection of potential candidates worthy of further study.  This approach could 278	
also be applied to the identification of other important mucosal pathogens whose route of 279	
entry begins in the nasopharynx. 280	
Materials and Methods: 281	
Materials: Cholera toxin was purchased from List Biological Laboratories. Ni-NTA resin 282	
was purchased from Qiagen. CloneEZ PCR cloning kits were obtained from Genscript 283	
Inc. All other reagents were obtained from Sigma or Thermo Fisher Scientific.   284	
Selection of protein candidates by bioinformatic analysis in silico 285	
We chose 42 S. pneumoniae sequences (including some finished and others in draft 286	
form) from the integrated microbial genomes website (http://img.jgi.doe.gov/cgi-287	
bin/w/main.cgi). Beginning with the TIGR4 strain, we identified 335 proteins with a 288	
secretion signal peptide and 15 proteins with possible cell wall anchor motifs. The 289	
protein library was then narrowed down to 76 proteins based on the following 290	
parameters chosen a priori: 291	
a.  Conservation across all 42 sequences defined as >90% identity at the amino acid 292	
level (reduced to 203).  293	
b. Exclusion of proteins with >40% homology with proteins in the human genome 294	
(reduced to 160).  295	
c. Exclusion of proteins containing an extracellular domain smaller than 100 amino 296	
acids (to focus on proteins more likely to be accessible to antibodies in the presence 297	
of polysaccharide capsule; reduced to 88)  298	
We specifically excluded previously-studied antigens (including PsaA (38), SP2018 and 299	
SP0148 (21), StkP and PcsB (19), Pht family proteins (39)) in order to focus on novel 300	
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antigens. The breakdown of the 76 proteins (see table S1) is as follows: 23 hypothetical 301	
proteins, 17 proteins proposed to play roles in substrate binding and transportation, 17 302	
proteins with predicted enzymatic activity and 19 others with unknown or hypothetical 303	
functions. Only extracellular domains without signal peptides or transmembrane regions 304	
were cloned.  305	
Construction of the pneumococcal expression library. 306	
The extracellular domains of selected proteins were amplified by PCR using TIGR4 307	
genomic DNA as template and then integrated into pET21b expression vectors using the 308	
CloneEZ PCR cloning kit. Two large (>250 kDa) proteins (SP0648 and SP1154) proved 309	
difficult to purify full-length. We divided each amino acid sequence into 3 parts based on 310	
predictions of their secondary structure by BCL::Jufo (http://meilerlab.org/index.php/ 311	
servers/show?s_id=5), making truncations in unconserved sequence areas, and purified 312	
each fragment separately. The two possible extracellular domains of one protein, 313	
SP0662, were both cloned and designated SP0662-1 and SP0662-2. Thus the final 314	
protein library consists of 81 proteins and peptides. Plasmid inserts were sequenced by 315	
Genewiz Inc. for confirmation. 316	
Protein Purification. E. coli transformants containing the cloned proteins were grown to 317	
OD600=0.6 and protein expression induced overnight with 0.2 mM IPTG at 16°C. Cells 318	
were spun down and pellets resuspended in lysis buffer (20 mM Tris-HCl, 500 mM NaCl, 319	
pH8.0) and lysed by sonication. The proteins of interest were purified from supernatants 320	
over a Ni-NTA column and eluted in imidazole buffer. Elutions containing each protein 321	
were combined and purified over a gel-filtration column in 20 mM Tris-HCl, 150 mM 322	
NaCl, pH 8.0.  323	
Stimulation of mouse immune cells and human adenoidal cells 324	
Splenocytes were harvested from mice that were either immunized with SPWCV 325	
intranasally or colonized intranasally with S. pneumoniae strain 0603 (6B serotype) (29). 326	
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Stimulations were carried out for 3 days with 5 µg/ml of each protein at 37ºC with 5% 327	
CO2. Plates were then spun to pellet the cells, after which the supernatants were 328	
collected and assayed for IL-17A using a mouse IL-17A ELISA kit (R&D Systems, Inc). 329	
Human adenoidal mononuclear cells from children undergoing adenoidectomy were 330	
separated on Ficoll gradients and cultured at 1x106 cells per well in 48 well plates. Cells 331	
were stimulated with 8 µg/ml of recombinant proteins or SPWCA at a concentration 332	
representing 1x106 cfu/ml of killed bacteria for 7 days and supernatants assayed for IL-333	
17A and IL-22 concentrations using human IL-17A and IL-22 ELISA kits (eBioscience). 334	
Ranking of antigens. Cytokine responses to each protein were ranked based on the 335	
average of the rankings among all responses to all the proteins in the cells from each 336	
donor (child or mouse) in each screen, instead of their actual values, to minimize the 337	
effects of variation in the responsiveness of the cells of each individual.  In each 338	
experiment, the protein with the greatest cytokine response was allocated the highest 339	
rank and each subsequent protein was assigned a chronological rank in the decreasing 340	
order of their responses. Proteins that had responses lower than that of unstimulated 341	
cells were all numbered “1”. The ranking numbers from each experiment were averaged 342	
to calculate the final rank of each protein.  343	
Immunization and challenge of mice. Female C57BL/6J mice (Jackson lab) were used 344	
in all experiments. All animal studies were approved by our local animal ethics 345	
committee. The age at time of first immunization was 4-6 weeks. Intranasal (i.n.) 346	
immunization was done by instilling 20 µl of saline with 1 µg of cholera toxin (CT) as a 347	
control, or CT mixed with 10 µg of antigen as specified, atraumatically into 348	
unanesthetized mice twice at a one-week interval. Blood was drawn 3 weeks after the 349	
last immunization, and assayed for IL-17A production upon stimulation with 5 µg/ml of 350	
the corresponding protein for 6 days. Nasopharyngeal colonization with the clinical 351	
pneumococcal isolate 0603 (serotype 6B) was carried out as previously described (29).  352	
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IL-17A depletion. Anti-IL-17A monoclonal (clone 17F3) and matching isotype-control 353	
antibodies were purchased from BioXcell. Mice were injected intraperitoneally with a 354	
dose of 150 µg per mouse 24 hours before and 3 days after infection.  355	
Statistical analysis. Correlation was analyzed by the nonparametric Spearman method. 356	
NP colonization densities were compared by the Mann-Whitney U test. Both were done 357	
using PRISM (version 7.0a, GraphPad Software, Inc).  358	
  359	
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Table 1 Protective antigens against pneumococcal colonization  514	
 515	
 516	
a, top 50% in human IL-17A screen; b, top 50% in murine WCV screen; c, top 50% in 517	
exposed murine screen; d, not in any top 50% screen, e, SP0648 consisted of three 518	
separate constructs, all of which were in the top 50% of all screens. 519	
 520	
 521	
 522	
 Gene name Annotation 
1 SP0321 b PTS system, IIA component 
2 SP0648 a,b,c,e Beta-galactosidase 
3 SP0662 a,b,c Sensor histidine kinase 
4 SP0742 a Hypothetical protein 
5 SP0757a,b,c Cell division protein FtsX 
6 SP0785 a,b,c Hypothetical protein 
7 SP0787 a,c Hypothetical protein 
8 SP0878 b SpoE family protein 
9 SP0899 b Hypothetical protein 
10 SP1032 a,b,c Iron-compound ABC transporter 
11 SP1069d Hypothetical protein 
12 SP1154-2 a IgA1-specific metallopeptidase 
13 SP1386 a,c Spermidine/putrescine ABC transporter 
14 SP1479 b Peptidoglycan N-acetylglucosamine deacetylase A 
15 SP1500 b,c Amino acid ABC transporter substrate-binding protein 
16 SP1683 a,b,c Carbohydrate ABC transporter substrate-binding protein 
	 21	
 523	
 Table 2 Hit	rate	in	the	top	50%	responders	in	different	screens 524	
 525	
 526	
 527	
 528	
 529	
 530	
 531	
 532	
 533	
 534	
 535	
Top 50% responders from ranked screen results of immunized mice (WCV), 536	
exposed mice (exposed) and human IL-17A (human). Each screen was ranked and then 537	
the top 50% or bottom 50% of proteins in the rankings were selected and overlap 538	
between these antigens was shown here. 539	
 540	 	541	
  542	
Screens		 Hit	rate	in	top	50%	 Hit	rate	in	bottom	50%	All	three	 8/13	(61.5%)	 1/9	(11.1%)	Human/WCV	 8/14	(57.1%)	 1/13	(7.7%)	Human/Exposed	 10/21	(47.6%)	 4/18	(22.2%)	WCV/Exposed	 9/16	(56.3%)	 3/17	(17.6%)	Human	 12/27	(44.4%)	 6/27	(22.2%)	WCV	 12/28	(42.9%)	 6/28	(21.4%)	Exposed	 11/28	(39.3%)	 7/28	(25%)	
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Figure legends 543	
Figure 1. IL-17A and IL-22 responses to SPWCV are positively correlated with donors’ 544	
ages. Adenoidal cells were stimulated with SPWCV and IL-17A and IL-22 were 545	
measured from the cell supernatant. The correlations were evaluated using the 546	
Spearman test.  547	
Figure 2. Responses of human adenoidal cells to stimulation with each protein or with 548	
whole cell vaccine. Human adenoidal mononuclear cells were stimulated with 8 µg/ml of 549	
recombinant proteins or SPWCA at a concentration representing 1x106 cfu/ml of killed 550	
bacteria for 7 days and cytokines were measured with ELISA. The graph is presented as 551	
mean±SEM. The antigens used for screening are: SP0079, SP0084, SP0092, SP0098, 552	
SP0127, SP0149, SP0191, SP0198, SP0249, SP0346, SP0435, SP0453, SP0564, 553	
SP0582, SP0601, SP0604, SP0617, SP0620, SP0629, SP0648-1, SP0648-2, SP0648-3, 554	
SP0659, SP0662-1, SP0662-2, SP0678, SP0724, SP0742, SP0757, SP0785, SP0787, 555	
SP0878, SP0899, SP1002, SP1032, SP1069, SP1154-2, SP1386, SP1404, SP1479, 556	
SP1500, SP1534, SP1545, SP1560, SP1652, SP1683, SP1826, SP1872, SP1942, 557	
SP2070, SP2083, SP2145, SP2192, SP2197, SP2207, SP2218 and SPWCV (from left 558	
to right).  SP0321 was toxic to human cells and was not used in human screens. 559	
Figure 3. Responses of murine splenocytes to stimulation with each protein or with 560	
whole cell vaccine. Mice splenocytes were stimulated with 5 µg/ml of recombinant 561	
proteins or SPWCA at a concentration representing 1x106 cfu/ml of killed bacteria for 3 562	
days and IL-17A was measured with ELISA. The graph is presented as mean±SEM. The 563	
antigens used for screening are: SP0079, SP0084, SP0092, SP0098, SP0127, SP0149, 564	
SP0191, SP0198, SP0249, SP0321, SP0346, SP0435, SP0453, SP0564, SP0582, 565	
SP0601, SP0604, SP0617, SP0620, SP0629, SP0648-1, SP0648-2, SP0648-3, SP0659, 566	
SP0662-1, SP0662-2, SP0678, SP0724, SP0742, SP0757, SP0785, SP0787, SP0878, 567	
SP0899, SP1002, SP1032, SP1069, SP1154-2, SP1386, SP1404, SP1479, SP1500, 568	
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SP1534, SP1545, SP1560, SP1652, SP1683, SP1826, SP1872, SP1942, SP2070, 569	
SP2083, SP2145, SP2192, SP2197, SP2207, SP2218 and SPWCV (from left to right). 570	
(A) IL-17A levels following stimulation of splenocytes from SPWCV immunized mice. (B) 571	
IL-17A levels following stimulation of splenocytes from pneumococcus-exposed mice. 572	
Figure 4. Protection against colonization by antigens from the surface protein library. 573	
Mice were immunized with 10 µg of each protein and 1 µg of cholera toxin twice weekly 574	
and challenged 4 weeks after the last immunization with a serotype 6B clinical strain. 575	
Nasal wash was collected 7 days later and bacterial CFU was determined by plating. 576	
Each dot represents CFU recovered from one mouse and the lines for each column 577	
represent geometric means. Colonization rates in mice receiving antigen plus adjuvant 578	
CT immunization were compared to those in control mice (receiving CT alone) using the 579	
unpaired nonparametric Mann-Whitney test. *, p<0.05; **, p<0.01; ***, p<0.001. 580	
Figure 5. Protection against nasal colonization conferred by proteins is IL-17A 581	
dependent. Mice were immunized with top-ranked antigens identified via the human 582	
screen (SP0648-1, SP0662-1 and SP0742) or via the mouse screen (SP0648-3, 583	
SP0757 and SP1500) intranasally. Mice were immunized with 10 µg of each protein and 584	
1 µg of cholera toxin twice weekly and challenged 4 weeks after the last immunization 585	
with a serotype 6B clinical strain. Mice received either anti-IL-17A or isotype control 586	
antibody one day prior to and 3 days after the infection.   Statistical analysis was 587	
performed with unpaired nonparametric Mann-Whitney test. n.s, not significant; *, 588	
p<0.05; ****, p<0.0001. 589	
Figure 6. Correlation between human IL-17A and IL-22 screens. The ranking of each 590	
antigen was analyzed for their correlation between each screen using nonparametric 591	
Spearman method.  592	
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